A recent study published in the journal Neuropharmacology provides evidence that a single dose of the psychedelic compound N,N-dimethyltryptamine can produce rapid and long-lasting antidepressant effects in mice. The research suggests that this naturally occurring hallucinogen might also reduce anxiety, offering a potential advantage over existing fast-acting treatments like S-ketamine. These findings highlight the promise of psychedelic compounds as future therapies for severe, treatment-resistant mental health conditions. Major depressive disorder is a widespread psychiatric condition that affects millions of people globally. Standard treatments typically take several weeks to begin working, leaving patients vulnerable during the waiting period. Approximately a third of these individuals do not respond to traditional medications, leading to a diagnosis of treatment-resistant depression. In recent years, medical professionals have sought out faster-acting alternatives to help these patients. Ketamine, a medication originally used for anesthesia, has become a prominent rapid-acting antidepressant. A specific version of this drug, known as S-ketamine, is now an approved nasal spray for treatment-resistant depression. At the same time, scientists have renewed their interest in serotonergic psychedelics, which are …